Hardman Johnston Global Advisors LLC Sells 34,124 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Hardman Johnston Global Advisors LLC sold 34,124 shares of Edwards Lifesciences, trimming its position by 9.7% to 316,770 shares valued at about $27.0M (≈0.05% of EW and 1.3% of the fund's portfolio).
• Corporate insiders have been net sellers — CFO Scott B. Ullem sold 13,000 shares and VP Donald E. Bobo Jr. sold 24,000 shares, with insiders offloading a total of 86,058 shares (~$7.12M) in the past 90 days; insiders now own about 0.31% of the company.
• Wall Street is broadly constructive: Edwards carries an average "Moderate Buy" rating with a mean target of $95.96 after several upgrades, while the latest quarter slightly missed EPS by $0.04 but revenue rose 13.3% and Q1 2026 guidance is $0.70–$0.76 EPS.

Hardman Johnston Global Advisors LLC lowered its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 9.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 316,770 shares of the medical research company's stock after selling 34,124 shares during the quarter. Edwards Lifesciences comprises 1.3% of Hardman Johnston Global Advisors LLC's investment portfolio, making the stock its 22nd largest holding. Hardman Johnston Global Advisors LLC owned approximately 0.05% of Edwards Lifesciences worth $27,005,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new position in Edwards Lifesciences during the 3rd quarter valued at about $238,688,000. Jennison Associates LLC grew its holdings in Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock valued at $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock valued at $1,478,425,000 after acquiring an additional 1,423,365 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Edwards Lifesciences by 114.5% during the 3rd quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company's stock valued at $161,055,000 after acquiring an additional 1,111,139 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several research reports. Wolfe Research raised Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. Canaccord Genuity Group set a $87.00 price objective on Edwards Lifesciences and gave the company a "hold" rating in a research report on Wednesday, December 17th. Evercore reiterated an "outperform" rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 5th. Truist Financial set a $89.00 target price on Edwards Lifesciences and gave the company a "hold" rating in a report on Wednesday, February 11th. Finally, Wells Fargo & Company upped their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $95.96.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company's stock, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the sale, the vice president directly owned 21,266 shares of the company's stock, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 86,058 shares of company stock valued at $7,118,636 in the last ninety days. Corporate insiders own 0.31% of the company's stock.

Edwards Lifesciences Trading Down 0.0%

Edwards Lifesciences stock opened at $77.85 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a one year low of $67.13 and a one year high of $87.89. The stock has a market capitalization of $44.88 billion, a PE ratio of 42.54, a price-to-earnings-growth ratio of 2.03 and a beta of 0.95. The business's fifty day moving average is $81.41 and its 200 day moving average is $82.04.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same period in the prior year, the company posted $0.59 EPS. The firm's revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.